IL212922D0 - Antibody formulation - Google Patents

Antibody formulation

Info

Publication number
IL212922D0
IL212922D0 IL21292211A IL21292211A IL212922D0 IL 212922 D0 IL212922 D0 IL 212922D0 IL 21292211 A IL21292211 A IL 21292211A IL 21292211 A IL21292211 A IL 21292211A IL 212922 D0 IL212922 D0 IL 212922D0
Authority
IL
Israel
Prior art keywords
antibody formulation
antibody
formulation
Prior art date
Application number
IL21292211A
Other versions
IL212922A (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to EP08170884A priority Critical patent/EP2196476A1/en
Priority to PCT/EP2009/066675 priority patent/WO2010066762A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL212922D0 publication Critical patent/IL212922D0/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40637230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL212922(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of IL212922A publication Critical patent/IL212922A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/245IL-1
IL212922A 2008-12-10 2011-05-16 Stable liquid formulations comprising an antibody to il-1beta and syringes and autoinjectors comprising the same IL212922A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP08170884A EP2196476A1 (en) 2008-12-10 2008-12-10 Antibody formulation
PCT/EP2009/066675 WO2010066762A1 (en) 2008-12-10 2009-12-09 Antibody formulation

Publications (2)

Publication Number Publication Date
IL212922D0 true IL212922D0 (en) 2011-07-31
IL212922A IL212922A (en) 2019-02-28

Family

ID=40637230

Family Applications (2)

Application Number Title Priority Date Filing Date
IL212922A IL212922A (en) 2008-12-10 2011-05-16 Stable liquid formulations comprising an antibody to il-1beta and syringes and autoinjectors comprising the same
IL264316A IL264316D0 (en) 2008-12-10 2019-01-17 Stable liquid formulations comprising an antibody to il-1beta, syringes and autoinjectors comprising the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL264316A IL264316D0 (en) 2008-12-10 2019-01-17 Stable liquid formulations comprising an antibody to il-1beta, syringes and autoinjectors comprising the same

Country Status (29)

Country Link
US (2) US20110236398A1 (en)
EP (3) EP2196476A1 (en)
JP (3) JP6143416B2 (en)
KR (2) KR20170044211A (en)
CN (2) CN104399076A (en)
AU (1) AU2009324371B2 (en)
BR (1) BRPI0922730A2 (en)
CA (1) CA2745938C (en)
CO (1) CO6361952A2 (en)
CY (1) CY1117735T1 (en)
DK (1) DK2376533T3 (en)
EC (1) ECSP11011192A (en)
ES (1) ES2579835T3 (en)
HK (1) HK1159130A1 (en)
HR (1) HRP20160754T1 (en)
HU (1) HUE028408T2 (en)
IL (2) IL212922A (en)
MA (1) MA33023B1 (en)
MX (1) MX2011006242A (en)
MY (2) MY166050A (en)
NZ (1) NZ592918A (en)
PE (1) PE03422012A1 (en)
PL (1) PL2376533T3 (en)
PT (1) PT2376533T (en)
RU (2) RU2563179C2 (en)
SM (1) SMT201600222B (en)
TN (1) TN2011000229A1 (en)
WO (1) WO2010066762A1 (en)
ZA (1) ZA201103362B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
CN107496917A (en) 2010-02-26 2017-12-22 诺沃—诺迪斯克有限公司 Stable antibody containing compositions
KR101903931B1 (en) 2010-03-01 2018-10-02 바이엘 헬스케어 엘엘씨 Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
AR082319A1 (en) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Producing an N-acetylgalactosamine-6-sulfatase active highly phosphorylated human and their uses
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
TWI621625B (en) 2010-09-17 2018-04-21 Baxalta Inc Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph
EP2857413A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
WO2013090648A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
FI123630B (en) 2011-10-24 2013-08-30 Teknologian Tutkimuskeskus Vtt Process for the preparation of the films on substrates NFC
US20140348848A1 (en) 2011-12-02 2014-11-27 Dhananjay Kaul Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US20150064235A1 (en) 2012-03-30 2015-03-05 Moderna Therapeutics, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
CA2883343A1 (en) 2012-09-05 2014-03-13 Tracon Pharmaceuticals, Inc. Antibody formulations and uses thereof
PE10792015A1 (en) * 2012-09-20 2015-08-07 Morphosys Ag Treatment for Rheumatoid Arthritis
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
WO2014143909A1 (en) * 2013-03-15 2014-09-18 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
TW201534323A (en) 2013-04-29 2015-09-16 Sanofi Sa Anti-IL-4/anti-IL-13 bispecific antibody formulations
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
JP2017521370A (en) * 2014-05-28 2017-08-03 ノノ インコーポレイテッド Lyophilized formulation of Tat-NR2B9c containing acetylated scavenger
WO2016034648A1 (en) * 2014-09-03 2016-03-10 Medimmune Limited Stable anti-il-4r-alpha antibody formulation
US10155820B2 (en) 2014-11-12 2018-12-18 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AU2017298656A1 (en) * 2016-07-21 2019-02-07 Novartis Ag Use of the IL-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
PE64396A1 (en) 1995-01-23 1997-01-28 Hoffmann La Roche Accessory protein receptor Interleukin 1
ES2435462T3 (en) 1995-07-27 2013-12-19 Genentech, Inc. Isotonic lyophilized protein formulation stable
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
TWI302149B (en) 1999-09-22 2008-10-21 Squibb Bristol Myers Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
BR0112026A (en) * 2000-06-29 2003-05-20 Abbott Lab Antibodies with dual specificity and methods of production and use
AU7673701A (en) * 2000-08-04 2002-02-18 Chugai Pharmaceutical Co Ltd Protein injection preparations
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US20030138417A1 (en) * 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
GT200600031A (en) * 2005-01-28 2006-08-29 Formulation anti beta
NZ561137A (en) * 2005-03-08 2011-09-30 Pharmacia & Upjohn Co Llc Stable anti-CTLA-4 antibody compositions with chelating agents
MX2007014148A (en) * 2005-05-19 2008-01-11 Amgen Inc Compositions and methods for increasing the stability of antibodies.
CA2626214C (en) 2005-10-26 2016-06-21 Novartis Ag Novel use of il-1beta compounds
CN201044845Y (en) * 2006-10-28 2008-04-09 李开元 Automatic syringe
PE14772008A1 (en) * 2006-12-11 2008-10-18 Hoffmann La Roche Mab lyophilized formulation Abeta
WO2008116103A2 (en) * 2007-03-22 2008-09-25 Imclone Llc Stable antibody formulations
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery

Also Published As

Publication number Publication date
RU2015132431A (en) 2018-12-24
RU2011127913A (en) 2013-01-20
KR101762966B1 (en) 2017-07-31
AU2009324371B2 (en) 2013-10-10
PL2376533T3 (en) 2016-09-30
CY1117735T1 (en) 2017-05-17
CA2745938C (en) 2018-04-24
US20120315285A1 (en) 2012-12-13
IL212922A (en) 2019-02-28
TN2011000229A1 (en) 2012-12-17
US8623367B2 (en) 2014-01-07
EP2376533A1 (en) 2011-10-19
JP2018168158A (en) 2018-11-01
SMT201600222B (en) 2016-08-31
MA33023B1 (en) 2012-02-01
ES2579835T3 (en) 2016-08-17
RU2563179C2 (en) 2015-09-20
JP2012511540A (en) 2012-05-24
ECSP11011192A (en) 2011-08-31
AU2009324371A1 (en) 2011-06-23
IL264316D0 (en) 2019-02-28
JP6143416B2 (en) 2017-06-07
MX2011006242A (en) 2011-06-24
MY166050A (en) 2018-05-22
CN104399076A (en) 2015-03-11
WO2010066762A1 (en) 2010-06-17
CA2745938A1 (en) 2010-06-17
EP3072906A1 (en) 2016-09-28
EP2196476A1 (en) 2010-06-16
PE03422012A1 (en) 2012-04-24
BRPI0922730A2 (en) 2018-11-06
CN102245639A (en) 2011-11-16
CO6361952A2 (en) 2012-01-20
RU2015132431A3 (en) 2018-12-24
SI2376533T1 (en) 2016-07-29
JP2015231997A (en) 2015-12-24
DK2376533T3 (en) 2016-06-27
HUE028408T2 (en) 2016-12-28
US20110236398A1 (en) 2011-09-29
CN102245639B (en) 2014-12-24
HK1159130A1 (en) 2016-10-14
PT2376533T (en) 2016-07-13
KR20120009421A (en) 2012-01-31
ZA201103362B (en) 2012-01-25
HRP20160754T1 (en) 2016-08-12
EP2376533B1 (en) 2016-03-30
MY157772A (en) 2016-07-29
NZ592918A (en) 2012-12-21
KR20170044211A (en) 2017-04-24

Similar Documents

Publication Publication Date Title
IL209916D0 (en) Mucleoside cyclicphosphates
GB0809631D0 (en) Zonesense
TWI464404B (en) Dreiachsiger beschleunigungssensor
EP2329415A4 (en) Data-tier application component
TWI523866B (en) Novel anti-cmet antibody
SI2949666T1 (en) Human anti-alpha-synuclein antibodies
ZA201106503B (en) Antibody formulation
EP2077859A4 (en) Antibody formulation
ZA201102119B (en) Improved antibody libraies
ZA201003907B (en) Antibody formulation
IL211295A (en) Stable liquid antibody formulation
HK1159130A1 (en) Antibody formulation
EP2358392A4 (en) Antibody formulation
HK1159157A1 (en) Organ-on-a-chip-device
DK200970290A (en) Gaskompressionssystem
TWI464172B (en) Pyrazolo-quinazolines
TWI439479B (en) Hydroxyl-functionalised polyurethane-hotmelt-prepolymer
EP1987067A4 (en) Antibody formulation
ZA201008024B (en) Anti-flt3 antibodies
EP2241578A4 (en) Anti-cldn6 antibody
TWI623323B (en) Antibody formulation
HK1161239A1 (en) Pyridine-3-carboxyamide derivative -3-
EP2138576A4 (en) Anti-claudin-4 antibody
TWI477054B (en) Photovoltaik-vorrichtung
TWI538630B (en) Sportwear